Congratulations to the 2024 NMD4C Early Career Awards Recipients

We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams. This year, the NMD4C awarded two awards as a part of this program: Early Career Biomedical Researcher of the Year, and Early Career Publication of the Year.

 

Early Career Biomedical Researcher of the Year award:

Dr Mireille KhachoDr. Mireille Khacho | Assistant Professor, Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa

Dr. Mireille Khacho’s research focuses on the role of mitochondrial function and dynamics in key cellular processes that regulate stem cell function in tissue homeostasis, the fundamental behavior of mitochondria in muscle stem cells, and the underlying role of mitochondrial dysfunction in degenerative disorders. As an early-career scientist, Dr. Khacho has established herself as an emerging international leader in neuromuscular research while holding a Tier 2 Canada Research Chair in Mitochondrial Dynamics and Regenerative Medicine. Her excellence and research impact has been recognized through attracting over $2.7 million in peer-reviewed funding, publishing as lead or corresponding author in prestigious journals such as Cell Stem Cell, and obtaining significant recognitions including the J.P. Bickell Award and the Stem Cell Network Young Investigator Award.

Early Career Publication of the Year:

MYTHO is a novel regulator of skeletal muscle autophagy and integrity from Dr. Jean-Philippe Leduc Gaudet, published in the journal Nature Communications.

Dr. Jean-Philippe Leduc Gaudet | Assistant Professor in the Medical Biology Department at Université du Québec à Trois-Rivières (UQTR), Université du Québec à Trois-Rivières

Dr. Jean-Philippe Leduc Gaudet’s research is focused on the various signaling pathways that control protein breakdown and protein synthesis, with a particular emphasis on the discovery and characterization of novel genes that are involved in muscular diseases. Dr. Leduc Gaudet’s publication “MYTHO is a novel regulator of skeletal muscle autophagy and integrity“ suggests that dysregulated expression of the newly identified Mytho gene may contribute to human muscular diseases, opening new paths to understanding the fundamental importance of proteolytic signaling in skeletal muscle health. This paper was featured on the Nature Communications Editors’ Highlights webpage, and he was recently invited to publish a highlight of this work in the prestigious journal Autophagy.

Learn more about each of the 2024 award recipients!

Through these awards, the NMD4C provides a method of recognizing outstanding achievement by early career neuromuscular researchers and clinicians on behalf of the Canadian neuromuscular community. Recipients receive a tangible accolade to bolster their academic CVs in pursuit of future academic appointments and grant applications. This award program is a part of the network’s broader strategy to provide support for Canadian early-career neuromuscular investigators.

 

Early career investigators are at a stage in their careers where finding the funding and academic appointments to continue their research programs and clinical work is integral to their career progression in the field of neuromuscular care and research. These applications are highly competitive, and it is our hope that receiving an NMD4C award can help support and strengthen these applications to secure critical research funding and academic appointments.”

– Dr. Natasha Chang, Assistant Professor, Department of Biochemistry, McGill University and NMD4C Steering Committee Investigator

 

Congratulations to this year’s award winners and thank you to all those who submitted nominations for these awards; we look forward to hosting this competition again for the coming year. More information on the application process for 2025 will be available on our early-career awards page.

Congratulations to the 2024 early career award winners. Dr Mireille Khacho and Dr Jean-Philippe Leduc Gaudet.

Read next...

NMD4C logo with text reading 'Canadian neuromuscular clinical trials network', MDC and IMHA logos at bottom.

NMD4C Launch Canadian Neuromuscular Clinical Trial Network

We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.

Event organizers and participants from SMA outcome measures training, March 2024 in Quebec.

Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network

This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted. 

MDC award $900 000 towards clinical and translational research projects in 2024.

MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants

Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.

SMA outcome measures training graphic

SMA Outcome Measures Training for Physiotherapists and Occupational Therapists

To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.

Pediatric Rare Disease Clinical Trials and Treatment Network - RareKids-CAN

MICYRN Secures $20 Million Grant from CIHR for a Pediatric Rare Disease Clinical Trials and Treatment Network

The NMD4C are excited to share that MICYRN’s success in securing a $20 million grant from CIHR Institute of Genetics to support the development and execution of RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network.

CNDR logo4x3

CNDR Welcomes Dr. Hugh McMillan as New Pediatric Lead

CNDR warmly welcome Dr. Hugh McMillan as the new CNDR Pediatric Lead and are grateful for the wealth of knowledge, expertise, and leadership he will bring to the role.